Cargando…

Prognostic Value of miRNAs in Head and Neck Cancers: A Comprehensive Systematic and Meta-Analysis

Head and Neck Cancer (HNC) is the sixth most common type of cancer across the globe, with more than 300,000 deaths each year, globally. However, there are currently no standardised molecular markers that assist in determining HNC prognosis. The literature for this systematic review and meta-analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumarasamy, Chellan, Madhav, Madurantakam Royam, Sabarimurugan, Shanthi, Krishnan, Sunil, Baxi, Siddhartha, Gupta, Ajay, Gothandam, K M, Jayaraj, Rama
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721479/
https://www.ncbi.nlm.nih.gov/pubmed/31349668
http://dx.doi.org/10.3390/cells8080772
_version_ 1783448352343457792
author Kumarasamy, Chellan
Madhav, Madurantakam Royam
Sabarimurugan, Shanthi
Krishnan, Sunil
Baxi, Siddhartha
Gupta, Ajay
Gothandam, K M
Jayaraj, Rama
author_facet Kumarasamy, Chellan
Madhav, Madurantakam Royam
Sabarimurugan, Shanthi
Krishnan, Sunil
Baxi, Siddhartha
Gupta, Ajay
Gothandam, K M
Jayaraj, Rama
author_sort Kumarasamy, Chellan
collection PubMed
description Head and Neck Cancer (HNC) is the sixth most common type of cancer across the globe, with more than 300,000 deaths each year, globally. However, there are currently no standardised molecular markers that assist in determining HNC prognosis. The literature for this systematic review and meta-analysis were sourced from multiple bibliographic databases. This review followed PRISMA guidelines. The Hazard Ratio (HR) was selected as the effect size metric to independently assess overall survival (OS), disease-free survival (DFS), and prognosis. Subgroup analysis was performed for individual highly represented miRNA. A total of 6843 patients across 50 studies were included in the systematic review and 34 studies were included in the meta-analysis. Studies across 12 countries were assessed, with China representing 36.7% of all included studies. The analysis of the survival endpoints of OS and DFS were conducted separately, with the overall pooled effect size (HR) for each being 1.825 (95% CI 1.527–2.181; p < 0.05) and 2.596 (95% CI 1.917–3.515; p < 0.05), respectively. Subgroup analysis was conducted for impact of miR-21, 200b, 155, 18a, 34c-5p, 125b, 20a and 375 on OS, and miR-21 and 34a on DFS. The pooled results were found to be statistically significant for both OS and DFS. The meta-analysis indicated that miRNA alterations can account for an 82.5% decrease in OS probability and a 159.6% decrease in DFS probability. These results indicate that miRNAs have potential clinical value as prognostic biomarkers in HNC, with miR-21, 125b, 34c-5p and 18a, in particular, showing great potential as prognostic molecular markers. Further large scale cohort studies focusing on these miRNAs are recommended to verify the clinical utility of these markers individually and/or in combination.
format Online
Article
Text
id pubmed-6721479
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67214792019-09-10 Prognostic Value of miRNAs in Head and Neck Cancers: A Comprehensive Systematic and Meta-Analysis Kumarasamy, Chellan Madhav, Madurantakam Royam Sabarimurugan, Shanthi Krishnan, Sunil Baxi, Siddhartha Gupta, Ajay Gothandam, K M Jayaraj, Rama Cells Review Head and Neck Cancer (HNC) is the sixth most common type of cancer across the globe, with more than 300,000 deaths each year, globally. However, there are currently no standardised molecular markers that assist in determining HNC prognosis. The literature for this systematic review and meta-analysis were sourced from multiple bibliographic databases. This review followed PRISMA guidelines. The Hazard Ratio (HR) was selected as the effect size metric to independently assess overall survival (OS), disease-free survival (DFS), and prognosis. Subgroup analysis was performed for individual highly represented miRNA. A total of 6843 patients across 50 studies were included in the systematic review and 34 studies were included in the meta-analysis. Studies across 12 countries were assessed, with China representing 36.7% of all included studies. The analysis of the survival endpoints of OS and DFS were conducted separately, with the overall pooled effect size (HR) for each being 1.825 (95% CI 1.527–2.181; p < 0.05) and 2.596 (95% CI 1.917–3.515; p < 0.05), respectively. Subgroup analysis was conducted for impact of miR-21, 200b, 155, 18a, 34c-5p, 125b, 20a and 375 on OS, and miR-21 and 34a on DFS. The pooled results were found to be statistically significant for both OS and DFS. The meta-analysis indicated that miRNA alterations can account for an 82.5% decrease in OS probability and a 159.6% decrease in DFS probability. These results indicate that miRNAs have potential clinical value as prognostic biomarkers in HNC, with miR-21, 125b, 34c-5p and 18a, in particular, showing great potential as prognostic molecular markers. Further large scale cohort studies focusing on these miRNAs are recommended to verify the clinical utility of these markers individually and/or in combination. MDPI 2019-07-25 /pmc/articles/PMC6721479/ /pubmed/31349668 http://dx.doi.org/10.3390/cells8080772 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kumarasamy, Chellan
Madhav, Madurantakam Royam
Sabarimurugan, Shanthi
Krishnan, Sunil
Baxi, Siddhartha
Gupta, Ajay
Gothandam, K M
Jayaraj, Rama
Prognostic Value of miRNAs in Head and Neck Cancers: A Comprehensive Systematic and Meta-Analysis
title Prognostic Value of miRNAs in Head and Neck Cancers: A Comprehensive Systematic and Meta-Analysis
title_full Prognostic Value of miRNAs in Head and Neck Cancers: A Comprehensive Systematic and Meta-Analysis
title_fullStr Prognostic Value of miRNAs in Head and Neck Cancers: A Comprehensive Systematic and Meta-Analysis
title_full_unstemmed Prognostic Value of miRNAs in Head and Neck Cancers: A Comprehensive Systematic and Meta-Analysis
title_short Prognostic Value of miRNAs in Head and Neck Cancers: A Comprehensive Systematic and Meta-Analysis
title_sort prognostic value of mirnas in head and neck cancers: a comprehensive systematic and meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721479/
https://www.ncbi.nlm.nih.gov/pubmed/31349668
http://dx.doi.org/10.3390/cells8080772
work_keys_str_mv AT kumarasamychellan prognosticvalueofmirnasinheadandneckcancersacomprehensivesystematicandmetaanalysis
AT madhavmadurantakamroyam prognosticvalueofmirnasinheadandneckcancersacomprehensivesystematicandmetaanalysis
AT sabarimuruganshanthi prognosticvalueofmirnasinheadandneckcancersacomprehensivesystematicandmetaanalysis
AT krishnansunil prognosticvalueofmirnasinheadandneckcancersacomprehensivesystematicandmetaanalysis
AT baxisiddhartha prognosticvalueofmirnasinheadandneckcancersacomprehensivesystematicandmetaanalysis
AT guptaajay prognosticvalueofmirnasinheadandneckcancersacomprehensivesystematicandmetaanalysis
AT gothandamkm prognosticvalueofmirnasinheadandneckcancersacomprehensivesystematicandmetaanalysis
AT jayarajrama prognosticvalueofmirnasinheadandneckcancersacomprehensivesystematicandmetaanalysis